Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) – MS Wkly

BioLineRx Ltd. (NASDAQ:BLRX) and Edge Therapeutics Inc. (:) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for BioLineRx Ltd. and Edge Therapeutics Inc.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both companies.

Insider and Institutional Ownership

The shares of both BioLineRx Ltd. and Edge Therapeutics Inc. are owned by institutional investors at 27.13% and 28.21% respectively. 3.46% are BioLineRx Ltd.s share held by insiders. On the other hand, insiders held about 5.63% of Edge Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Summary

BioLineRx Ltd. beats on 4 of the 6 factors Edge Therapeutics Inc.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and Genentechs Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:

Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly